Mitochondrial Replacement Therapy & Ooplasmic Transfer

The primary research record in Mitochondrial Replacement Therapy & Ooplasmic Transfer is stratified by study design so that meta-analyses and replicated randomised controlled trials (T1–T2) carry greater epistemic weight than observational cohorts (T3–T4) or preclinical laboratory work (T5). Leading graded findings establish the core empirical baseline: [T3] The PTEN-induced putative kinase protein 1 (PINK1) and ubiquitin (UB) ligase PARKIN direct damaged mitochondria for mitophagy. [22] [T4] Maternal Spindle Transfer into enucleated donor oocytes yields healthy live births with 100% parental nuclear DNA and <1% maternal mitochondrial carryover in couples with repeated embryonic arrest. [12]

Further clinical and mechanistic stratification across the literature demonstrates: [T5] Early pronuclear transfer performed shortly after pronuclear appearance achieves >85% zygote survival and reduces mitochondrial DNA carryover to <2%. [20] [T5] Accordingly, the presence of an mtDNA mutation in tumour tissue is a poor prognostic factor for immune checkpoint inhibitors in patients with melanoma or non-small-cell lung cancer. [10]

By contrast, interventions and hypotheses that remain experimental, subgroup-restricted, or unsupported by randomised endpoints include: Maternal Spindle Transfer (MST) (Trial only — Rescues cleavage-stage arrest into transferable euploid blastocysts; 6 live births confirmed; Avoids fertilizing a donor egg first; 99.9% parental DNA with young cytoplasmic ATP and metabolic factors.); Pronuclear Transfer (PNT) (Trial only — High survival (>85%) and blastocyst development in zygotes previously prone to 2- to 4-cell arrest; Clinically practiced in Ukraine and approved in the UK for mitochondrial disease prevention.); Germinal Vesicle Transfer (GVT) (Lab only — Allows the first meiotic division and chromosome segregation to occur inside young, ATP-rich cytoplasm; Theoretically the strongest way to prevent age-related Meiosis I nondisjunction at 40+, currently optimizing ex vivo maturation synchronization.).

Chronologically, the field evolved through key inflection points: in 1982, Mitochondrial DNA sequences of primates: tempo and mode of evolution. (The sequence differences range from 9 to 19% among species, in agreement with estimates from cleavage map comparisons, thus confirming that the rate of mtDNA evolution in primates is 5 to 10 times higher than in nuclear DNA); in 2016, Early Pronuclear Transfer Protocol Refined at Newcastle University (Hyslop and Herbert demonstrate <2% mtDNA carryover and normal blastocyst transcriptomes in Nature); in 2023, Safety and Feasibility of Metformin for Sepsis Induced AKI (Acute kidney injury (AKI) is an independent risk factor for death that affects 10-15% of hospitalized patients and more than 50% of patients admitted to the intensive care unit); in 2023, Six Healthy Live Births from Maternal Spindle Transfer in Athens/Barcelona Trial (Costa-Borges et al. publish complete clinical and pediatric follow-up of MST for idiopathic infertility).

Contested and frontier findings currently under investigation include: [T4 · Debated] Maternal Spindle Transfer into enucleated donor oocytes yields healthy live births with 100% parental nuclear DNA and <1% maternal mitochondrial carryover in couples with repeated embryonic arrest. (Costa-Borges et al., Fertility and Sterility 2023.) [T5 · Frontier / fringe] Accordingly, the presence of an mtDNA mutation in tumour tissue is a poor prognostic factor for immune checkpoint inhibitors in patients with melanoma or non-small-cell lung cancer. (Extracted from primary in vitro literature (2025, 281 citations).)

Methodological priorities and open empirical questions queued for the next research sweep across Mitochondrial Replacement Therapy & Ooplasmic Transfer focus on resolving subgroup effect sizes, causal mechanisms, and long-term outcomes:

• Pre-meiotic Germinal Vesicle Transfer (GVT) to rescue chromosome segregation before Meiosis I spindle formation in women aged 40–45
• Purified autologous oogonial/stem-cell mitochondrial injection protocols that eliminate even third-party mtDNA
• Large-scale multicentre randomised controlled trials with standardised live-birth and long-term offspring follow-up in Mitochondrial Replacement & Transfer.
• Age- and subgroup-stratified biomarker validation across diverse human populations.
• Germinal Vesicle Transfer (GVT) paired with Gameto Fertilo engineered IVM to rescue Meiosis I chromosome segregation in oocytes aged 40+